Suppr超能文献

利拉鲁肽给药及限热量饮食对超重/肥胖糖尿病前期患者脂蛋白谱的影响。

Effect of liraglutide administration and a calorie-restricted diet on lipoprotein profile in overweight/obese persons with prediabetes.

作者信息

Ariel D, Kim S H, Abbasi F, Lamendola C A, Liu A, Reaven G M

机构信息

Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.

Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.

出版信息

Nutr Metab Cardiovasc Dis. 2014 Dec;24(12):1317-22. doi: 10.1016/j.numecd.2014.06.010. Epub 2014 Jun 28.

Abstract

BACKGROUND AND AIMS

To evaluate the effects of 14 weeks of liraglutide plus modest caloric restriction on lipid/lipoprotein metabolism in overweight/obese persons with prediabetes.

METHODS AND RESULTS

Volunteers with prediabetes followed a calorie-restricted diet (-500 Kcal/day) plus liraglutide (n = 23) or placebo (n = 27) for 14 weeks. The groups were similar in age (58 ± 7 vs. 58 ± 8 years) and body mass index (31.9 ± 2.8 vs. 31.9 ± 3.5 kg/m(2)). A comprehensive lipid/lipoprotein profile was obtained before and after intervention using vertical auto profile (VAP). Weight loss was greater in the liraglutide group than in the placebo group (6.9 vs. 3.3 kg, p < 0.001), as was the fall in fasting plasma glucose concentration (9.9 mg/dL vs. 0.3 mg/dL, p < 0.001). VAP analysis revealed multiple improvements in lipid/lipoprotein metabolism in liraglutide-treated compared with placebo-treated volunteers, including decreases in concentrations of total cholesterol, low-density lipoprotein cholesterol and several of its subclasses, triglyceride, and non-high-density cholesterol. The liraglutide-treated group also had a significant shift away from small, dense low-density lipoprotein-particles, as well as decreases in apolipoprotein B concentration and ratio of apolipoprotein B/apolipoprotein A-1. There were no significant changes in the lipoprotein profile in the placebo-treated group.

CONCLUSION

Treatment with liraglutide plus modest calorie restriction led to enhanced weight loss, a decrease in fasting plasma glucose concentration, and improvement in multiple aspects of lipid/lipoprotein metabolism associated with increased cardiovascular disease (CVD) risk. The significant clinical benefit associated with liraglutide-assisted weight loss in a group at high risk for CVD - obese/overweight individuals with prediabetes - as seen in our pilot study, suggests that this approach deserves further study.

摘要

背景与目的

评估14周利拉鲁肽联合适度热量限制对糖尿病前期超重/肥胖者脂质/脂蛋白代谢的影响。

方法与结果

糖尿病前期志愿者遵循热量限制饮食(-500千卡/天)加用利拉鲁肽(n = 23)或安慰剂(n = 27),为期14周。两组在年龄(58±7岁对58±8岁)和体重指数(31.9±2.8对31.9±3.5千克/平方米)方面相似。干预前后采用垂直自动分析仪(VAP)获取全面的脂质/脂蛋白谱。利拉鲁肽组的体重减轻幅度大于安慰剂组(6.9千克对3.3千克,p<0.001),空腹血糖浓度下降幅度也是如此(9.9毫克/分升对0.3毫克/分升,p<0.001)。VAP分析显示,与安慰剂治疗的志愿者相比,利拉鲁肽治疗的志愿者在脂质/脂蛋白代谢方面有多项改善,包括总胆固醇、低密度脂蛋白胆固醇及其几个亚类、甘油三酯和非高密度胆固醇浓度降低。利拉鲁肽治疗组还显著减少了小而密的低密度脂蛋白颗粒,载脂蛋白B浓度和载脂蛋白B/载脂蛋白A-1比值也降低。安慰剂治疗组的脂蛋白谱无显著变化。

结论

利拉鲁肽联合适度热量限制治疗可增强体重减轻效果,降低空腹血糖浓度,并改善与心血管疾病(CVD)风险增加相关的脂质/脂蛋白代谢多个方面。如我们的初步研究所示,在CVD高风险人群——糖尿病前期肥胖/超重个体中,利拉鲁肽辅助体重减轻具有显著临床益处,表明这种方法值得进一步研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验